What does Checkpoint Therapeutics, Inc. do?

Jun 22 2025 06:54 PM IST
share
Share Via
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company focused on developing immune-enhanced combination treatments for solid tumor cancers. It has a market cap of approximately $370.71 million and reported a net profit of -$11 million as of March 2025.
Overview:
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company focused on the development and commercialization of immune-enhanced combination treatments for solid tumor cancers, operating within the Pharmaceuticals: Major industry and classified as a micro-cap company.

Financial Snapshot:
Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)
Market cap: USD 370.71 Million (Micro Cap)

Key Metrics:
Dividend Yield: 23.88%
Debt Equity: -2.03
Return on Equity: -345.95%
Price to Book: 22.75

Contact Details:
Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667
Tel: 1 212 5544366
Website: http://www.checkpointtx.com
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News